In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 101 to 150 of 434

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726	Technology appraisal guidance	TBC
Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)	NICE guideline	TBC
Diabetic retinopathy - ruboxistaurin [ID382]	Technology appraisal guidance	TBC
Digital hearing aids (Provisional title)	Health technology evaluation	TBC
Digital platforms to support rehabilitation before and after hip or knee replacement surgery	Health technology evaluation	TBC
Digital self-help for eating disorders: early value assessment	Health technology evaluation	TBC
Digital technologies delivering CBT for insomnia and insomnia symptoms (provisional title)	Health technology evaluation	TBC
Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early-value assessment	Health technology evaluation	22 January 2026
Digital technologies for multidisciplinary weight management	Health technology evaluation	TBC
Digital technologies to support asthma self-management: early value assessment	Health technology evaluation	17 April 2026
Digital technologies to support smoking cessation in secondary care patients: early value assessment	Health technology evaluation	TBC
Domestic violence and abuse: multi-agency working	NICE guideline	TBC
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]	Technology appraisal guidance	TBC
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]	Technology appraisal guidance	18 June 2026
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]	Technology appraisal guidance	TBC
Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency [ID6415]	Technology appraisal guidance	16 December 2025
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]	Highly specialised technology	TBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]	Technology appraisal guidance	TBC
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID6235	Technology appraisal guidance	TBC
Dupilumab for treating bullous pemphigoid [ID6479]	Technology appraisal guidance	TBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]	Technology appraisal guidance	TBC
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]	Technology appraisal guidance	TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]	Technology appraisal guidance	TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]	NICE guideline	TBC
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]	Technology appraisal guidance	TBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]	Technology appraisal guidance	TBC
Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]	Technology appraisal guidance	17 December 2025
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317	Technology appraisal guidance	TBC
Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]	Technology appraisal guidance	14 April 2027
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]	Technology appraisal guidance	TBC
Ectopic pregnancy and miscarriage: diagnosis and initial management (update)	NICE guideline	6 May 2026
Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy [ID6409]	Technology appraisal guidance	29 July 2026
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]	Technology appraisal guidance	TBC
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]	Technology appraisal guidance	TBC
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]	Technology appraisal guidance	TBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]	Technology appraisal guidance	TBC
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma	Interventional procedures guidance	TBC
Endoscopic submucosal dissection knives for the removal of gastrointestinal lesions	Health technology evaluation	TBC
Eneboparatide for treating chronic hypoparathyroidism [ID6532]	Technology appraisal guidance	TBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]	Technology appraisal guidance	15 June 2022
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6607]	Technology appraisal guidance	TBC
Ensitrelvir for treating COVID 19 [ID6231]	Technology appraisal guidance	TBC
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]	Technology appraisal guidance	25 February 2026
Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]	Technology appraisal guidance	3 September 2026
Epilepsies in children, young people and adults	NICE guideline	TBC
Epilepsies in children, young people and adults (extraordinary review)	NICE guideline	TBC
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]	Technology appraisal guidance	TBC
Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]	Technology appraisal guidance	TBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920	Technology appraisal guidance	TBC
Ex-situ machine perfusion devices for deceased donor liver transplants	Health technology evaluation	20 August 2026

Results per page

10
25
50
All